Gilder Gagnon Howe & Co. LLC raised its position in Nuvectra Corporation (NASDAQ:NVTR) by 4.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 996,557 shares of the company’s stock after purchasing an additional 43,126 shares during the period. Gilder Gagnon Howe & Co. LLC owned approximately 9.24% of Nuvectra Corporation worth $13,214,000 as of its most recent filing with the SEC.
Other large investors have also recently modified their holdings of the company. Gamco Investors INC. ET AL increased its stake in Nuvectra Corporation by 4.2% in the second quarter. Gamco Investors INC. ET AL now owns 35,194 shares of the company’s stock valued at $467,000 after purchasing an additional 1,434 shares in the last quarter. Rockefeller Financial Services Inc. increased its stake in Nuvectra Corporation by 3.2% in the second quarter. Rockefeller Financial Services Inc. now owns 107,523 shares of the company’s stock valued at $1,428,000 after purchasing an additional 3,338 shares in the last quarter. EAM Investors LLC bought a new stake in Nuvectra Corporation in the second quarter valued at approximately $752,000. Wells Fargo & Company MN increased its stake in Nuvectra Corporation by 1.3% in the second quarter. Wells Fargo & Company MN now owns 114,492 shares of the company’s stock valued at $1,520,000 after purchasing an additional 1,495 shares in the last quarter. Finally, Hodges Capital Management Inc. increased its stake in Nuvectra Corporation by 18.6% in the second quarter. Hodges Capital Management Inc. now owns 227,807 shares of the company’s stock valued at $3,025,000 after purchasing an additional 35,706 shares in the last quarter. 57.00% of the stock is owned by hedge funds and other institutional investors.
Shares of Nuvectra Corporation (NVTR) traded up $0.21 during mid-day trading on Tuesday, hitting $8.46. 74,200 shares of the stock traded hands, compared to its average volume of 59,143. The company has a quick ratio of 2.72, a current ratio of 2.90 and a debt-to-equity ratio of 0.37. Nuvectra Corporation has a 52 week low of $4.63 and a 52 week high of $15.00.
Nuvectra Corporation (NASDAQ:NVTR) last issued its quarterly earnings data on Wednesday, November 1st. The company reported ($1.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.16) by $0.07. Nuvectra Corporation had a negative net margin of 204.19% and a negative return on equity of 68.63%. The company had revenue of $7.60 million during the quarter, compared to the consensus estimate of $8.08 million. During the same quarter in the prior year, the firm earned ($0.92) earnings per share. The firm’s revenue was up 100.0% compared to the same quarter last year. research analysts anticipate that Nuvectra Corporation will post -4.77 EPS for the current fiscal year.
Several equities research analysts have recently issued reports on the stock. ValuEngine downgraded shares of Nuvectra Corporation from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Piper Jaffray Companies reissued a “hold” rating and set a $12.00 price objective on shares of Nuvectra Corporation in a research report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $12.00.
Nuvectra Corporation Profile
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.
Receive News & Ratings for Nuvectra Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra Corporation and related companies with MarketBeat.com's FREE daily email newsletter.